Rwanda Injectable HIV Prevention takes a bold step forward as the nation launches cabotegravir (CAB-LA), a long-acting injectable pre-exposure prophylaxis (PrEP).
This innovative medication, approved by the World Health Organization (WHO) in 2022, represents a transformative solution in the country’s ongoing fight against HIV.
PrEP medications are specifically designed for HIV-negative individuals to reduce the risk of infection. With CAB-LA, recipients begin with two injections four weeks apart, followed by injections every eight weeks. 
This schedule significantly simplifies the process compared to daily oral PrEP.
CAB-LA: A WHO-Approved HIV Prevention Solution
The World Health Organization endorsed CAB-LA as a safe and highly effective option for HIV prevention. In order to encourage worldwide adoption, WHO modified its guidelines in 2022 and underlined its significance for people who are at a significant risk of infection.
Rwanda is now one of the nations using this cutting-edge tool as part of an all-encompassing strategy to prevent HIV.
Tackling Adherence Challenges with Injectable PrEP
Daily oral PrEP has historically faced challenges with adherence. The introduction of CAB-LA addresses this issue by offering a bi-monthly injection, reducing the burden of daily medication.
According to Dr. Basile Ikuzo, Director of the HIV Prevention Unit at the Rwanda Biomedical Centre (RBC), the injectable form offers an opportunity to enhance client acceptability and broaden access to prevention tools.
Rwanda Targets High-Risk Groups with CAB-LA
Rwanda’s rollout of CAB-LA strategically targets high-risk groups, including sex workers and discordant couples. Initially, the program will pilot in two health centers to assess community response. Based on its success, the government plans to scale up the initiative across the nation by early 2025.
Over 10,000 individuals already use oral PrEP in Rwanda, including 30% of those categorized as high-risk. The country’s proactive approach has contributed to a decline in HIV prevalence, especially among female sex workers, where rates have dropped from 45% a decade ago to 35% today.
Rwanda’s Leadership in HIV Prevention
Rwanda has achieved remarkable progress in HIV management, meeting the UNAIDS “95-95-95” target. These goals ensure that 95% of people living with HIV know their status, 95% of those diagnosed receive treatment, and 95% achieve viral suppression.
The introduction of CAB-LA is indicative of Rwanda’s commitment to maintaining its leadership in HIV prevention while showcasing its innovative healthcare strategies.
The nationwide debut of Rwanda Injectable HIV Prevention serves as an inspiring model for other nations. With CAB-LA now part of its robust HIV prevention strategy, Rwanda demonstrates how prioritizing innovative and accessible healthcare solutions can create a lasting impact.
Read More:
